Figure S1 Mean change in hemoglobin in the placebo arm by initial anti-malarial treatment group in 2007 study.

Change in Hemoglobin at day 3 is compared to haemoglobin concentration at presentation with malaria and initiation of anti-malarial treatment. Thereafter the comparison is with baseline levels at day 3 after completion of anti-malarial treatment. Error bars represent the 95% confidence intervals.

From Day 30 onwards there was a larger Hb response in children who received anti-malarial therapy with CQ-SP compared to ACT. However, the drop in Hb from Day 0 to Day 3 and Day 7 in children who were initially treated with ACT was smaller than the drop in children initially treated with CQ-SP, although the difference was not significant resulting in similar levels of final Hb as indicated in the analysis to determine independent predictors of Day 90 Hb, in which Hb at Day 0 was the strongest predictor.
Figure S2. Percentage of participants with sub-microscopic malaria (qPCR) over time in the placebo group (2007 study) by initial anti-malaria treatment

There was no effect of initial anti-malaria treatment on parasite clearance up until 3 months post-malarial episode.
Figure S3. Box and whisker plot of urinary neopterin in the placebo group (2007 study) by initial anti-malaria treatment